J Pediatr Intensive Care 2016; 05(03): 108-112
DOI: 10.1055/s-0035-1569996
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Clinical Decision Support for Pediatric Blood Product Prescriptions

Eloa S. Adams
1   Department of Pediatric Intensive Care Medicine, Kaiser Permanente, Oakland Medical Center, Oakland, California, United States
,
Christopher A. Longhurst
2   Department of Pediatrics, Stanford University School of Medicine, Lucille Packard Children's Hospital, Palo Alto, California, United States
› Institutsangaben
Weitere Informationen

Publikationsverlauf

05. Juni 2015

07. Juni 2015

Publikationsdatum:
15. Dezember 2015 (online)

Preview

Abstract

Since the beginning of the 20th century, blood products have been used to effectively treat life-threatening conditions. Over time, we have come to appreciate the many benefits along with significant risks inherent to blood product transfusions. As such, recommendations for the safe and effective use of blood products have evolved over time. Current evidence supports the use of restrictive transfusion strategies that can avoid the risks of unnecessary transfusions. In spite of good evidence, there is a considerable amount of variability in transfusion practices across providers. Clinical decision support (CDS) is an effective tool capable of increasing adherence to evidence-based practices. CDS has been used successfully to improve adherence to transfusion guidelines. Pediatric literature demonstrates strong evidence for the use of CDS to improve appropriateness of red blood cell and plasma transfusion utilization. Further studies in more diverse settings with more standardized reporting are needed to provide more clarity around the effectiveness of CDS in blood product prescriptions.